A Role for Probiotics in Pediatric Inflammatory Bowel Disease—Is there Evidence to Support It?
are needed to answer these questions. Moreover, benefits regarding the use of probiotics need to be individually evaluated, as studies have shown that some probiotics represent a better option than others. Highly concentrated probiotics preparations (such as VSL#3) seem of greater interest. Finally, if probiotics were to become a treatment option, a process would need to be undertaken to have these agents officially recognized from national health authorities in order to allow some insurance coverage and ease the cost burden on many families. n
1. 2. 3. 4. 5. 6. 7. 8. 9.
World Health Organization (WHO). Guidelines for the Evaluation of Probiotics in Food: Joint FAO/WHO Working Group meeting, London Ontario, Canada, 30 April–1 May 2002.
Budarf ML, Labbé C, David G, Rioux JD, GWA studies: rewriting the story of IBD, Trends Genet, 2009;25(3):137–46.
Abraham C, Cho JH, Inflammatory bowel disease, N Engl J Med, 2009;361(21):2066–78.
Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W, Interleukin-10-deficient mice develop chronic enterocolitis, Cell, 1993;75:263–74.
Simon GL, Gorbach SL, Intestinal flora in health and disease, Gastroenterology, 1984;86:174–93.
Fabia R, Ar’Rajab A, Johansson ML, et al., Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat, Digestion, 1993;54:248–55.
Sauer CG, Kugathasan S, Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD, Gastroenterol Clin North Am, 2009;38(4):611–28.
Biancone L, Calabrese E, Petruzziello C, Pallone F, Treatment with biologic therapies and the risk of cancer in patients with IBD, Nat Clin Pract, 2007;4(2):78–91.
Heuschkel R, Afzal N, Wuerth A, Zurakowski D, Complementary medicine use in children and young adults with inflammatory bowel disease, Am J Gastroenterol, 2002;97(2):382–8.
10. Hering N, Schulzke J, Therapeutic options to modulate barrier defects in inflammatory bowel disease, Dig Dis, 2009;27:450–4.
11. Kruis W, Schutz E, Fric P, et al., Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerates colitis, Aliment Pharmacol Ther, 1997;11:853–8.
12. Sang LX, Chang B, Zhang WL, Wu XM, et al., Remission induction and maintenance effect of probiotics on ulcerative
colitis: a meta-analysis, World J Gastroenterol, 2010;16(15):1908–15.
13. Tursi A, Brandimarte G, Papa A, Giglio A, Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: a double-blind, randomized, placebo-controlled study, Am J Gastroenterol, 2010;105(10):2218–27.
14. Do V, Baird B, Kockler D. Probiotics for maintaining remission of ulcerative colitis in adults, Ann Pharmacother, 2010;44:565–71.
15. Henker J, Müller S, Laass MW, Schreiner A, et al., Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study, Z Gastroenterol, 2008;46(9):874–5.
16. Miele E, Pascarella F, Giannetti E, Quaglietta L, et al., Effect of a probiotic preparation (vsl#3) on induction and maintenance of remission in children with ulcerative colitis, Am J Gastroenterol, 2009;104(2):437–43.
17. Huynh HQ, Debruyn J, Guan L, et al., Probiotic preparation vsl#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study, Inflamm Bowel Dis, 2009;15(5):760–8.
18. Gionchetti P, Rizzello F, Helwig U, et al., Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial, Gastroenterology, 2003;124(5):1202–9.
19. Mimura T, Rizzello F, Helwig U, et al., Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis, Gut, 2004;53(1):108–14.
20. Schultz M, Timmer A, Herfarth HH, et al., Lactobacillus GG in inducing and maintaining remission of Crohn’s disease, BMC Gastroenterol, 2004;4:5.
21. Malchow HA, Crohn’s disease and Escherichia coli, A new approach in therapy to maintain remission of colonic Crohn’s disease?, J Clin Gastroenterol, 1997;25(4):653–8.
Hien Huynh, MBBS, FRACP, FRCPC, is an Associate Professor in the Department of Pediatrics at the University of Alberta and Head of the Division of Pediatric Gastroenterology and Nutrition. He is also Director of the Pediatric Inflammatory Bowel Disease program at the Stollery Children’s Hospital. He is a member of the Canadian Association of Gastroenterology (CAG), North American Society of Pediatric Gastroenterology and Nutrition (NASPGHAN), and the Gastroenterological Society of Australia.
22. Guslandi M, Mezzi G, Sorghi M, Testoni PA, Saccharomyces boulardii in maintenance treatment of Crohn’s disease, Dig Dis Sci, 2000;45(7):1462–4.
23. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F, Probiotics for maintenance of remission in Crohn’s disease, Cochrane Database Syst Rev, 2006;(4):CD004826.
24. Van Gossum A, Dewit O, Louis E, de Hertogh G, et al., Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection, Inflamm Bowel Dis, 2007;13(2):135–42.
25. Doherty GA, Bennett GC, Cheifetz AS, Moss AC, Meta- analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn’s disease, Aliment Pharmacol Ther, 2010;31(8):802–9.
26. Desreumaux P, Dewit O, Belaiche J, Savoye G, et al., Lactobacillus casei DN-114 OO1 strain in the prevention of post-op recurrence of Crohn’s disease: a randomized, double-blind placebo-controlled trial, DDW 2010, poster abstract.
27. Gupta P, Andrew H, Kirschner BS, Guandalini S, Is Lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study, J Pediatr Gastroenterol Nutr, 2000;31(4):453–7.
28. Guandalini S, Use of Lactobacillus GG in paediatric Crohn’s disease, Dig Liver Dis, 2002;34(Suppl 2):S63–5.
29. Bousvaros A, Guandalini S, Baldassano RN, et al., A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease, Inflamm Bowel Dis, 2005;11(9),833–9.
30. Sherman PM, Ossa JC, Johnson-Henry K, Unraveling mechanisms of action of probiotics, Nutr Clin Pract, 2009; 24(1):10–14.
US GASTROENTEROLOGY & HEPATOLOGY REVIEW
57
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100